In tumor-derived CXCL10+ cDCs, CD14+ monocyte markers (S100A8, S100A9) and CD16+ monocyte markers (CD16) were universally up-regulated compared with CLEC9A+, CD1C+, and LAMP3+ cDCs (Fig. 1F). The gene discussed is CXCL10; the disease is neoplasm.